Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Xvivo Perfusion AB (publ) (3XV.F)

Compare
25.30
+0.92
+(3.77%)
As of 10:52:19 AM GMT+2. Market Open.
Currency in SEK All numbers in thousands
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
822,415
822,415
597,542
415,292
258,386
Cost of Revenue
206,000
206,000
152,431
118,336
70,107
Gross Profit
616,415
616,415
445,111
296,956
188,279
Operating Expense
528,062
528,062
440,924
292,501
207,021
Operating Income
88,353
88,353
4,187
4,455
-18,742
Net Non Operating Interest Income Expense
111,595
111,595
90,334
1,029
19,471
Pretax Income
199,948
199,948
94,521
22,314
6,665
Tax Provision
27,766
27,766
2,701
3,887
-1,487
Net Income Common Stockholders
172,182
172,182
91,820
18,427
8,152
Diluted NI Available to Com Stockholders
172,182
172,182
91,820
18,427
8,152
Basic EPS
5.47
5.47
3.07
0.62
0.28
Diluted EPS
5.44
5.44
3.07
0.62
0.28
Basic Average Shares
31,499.47
31,499.47
29,935.15
29,525.95
28,845.69
Diluted Average Shares
31,650.11
31,650.11
29,935.15
29,525.95
28,936.08
Total Operating Income as Reported
88,353
88,353
4,187
6,409
-18,498
Total Expenses
734,062
734,062
593,355
410,837
277,128
Net Income from Continuing & Discontinued Operation
172,182
172,182
91,820
18,427
8,152
Normalized Income
172,182
172,182
91,820
18,644.46
8,184.55
Interest Income
--
--
8,850
2,123
--
Interest Expense
--
--
1,190
605
276
Net Interest Income
111,595
111,595
90,334
1,029
19,471
EBIT
88,353
88,353
4,187
22,919
6,941
EBITDA
88,353
88,353
4,187
65,086
39,198
Reconciled Cost of Revenue
206,000
206,000
152,431
118,336
70,107
Reconciled Depreciation
--
--
76,350
42,167
32,257
Net Income from Continuing Operation Net Minority Interest
172,182
172,182
91,820
18,427
8,152
Total Unusual Items Excluding Goodwill
-1,001
--
-1,001
-262
-41
Total Unusual Items
-1,001
--
-1,001
-262
-41
Normalized EBITDA
88,353
88,353
4,187
65,348
39,239
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
--
--
--
-44.54
-8.45
12/31/2021 - 7/22/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade